Key result
Histologic response to preoperative chemotherapy strongly predicted 10-year disease-free survival in Stage IIB osteogenic sarcoma, with 90% survival for complete versus 54% for little response.
Why the study?
What are the long-term survival outcomes and prognostic factors in patients with Stage IIB osteogenic sarcoma?
Cohort (n=271)
What are the long-term survival outcomes and prognostic factors in patients with Stage IIB osteogenic sarcoma?
In patients with Stage IIB osteogenic sarcoma, histologic response to preoperative chemotherapy is the strongest predictor of long-term disease-free survival.
Answers are grounded in this paper and cite their sources.
Histologic response may refine prognosis after chemotherapy for bone sarcomas; leaves open whether it should guide modern treatment adaptation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Glasser et al. (1991) conducted a cohort in Stage IIB Osteogenic Sarcoma (n=271). Histologic response to preoperative chemotherapy vs. Little response was evaluated on Disease-free survival at 10 years. Histologic response to preoperative chemotherapy strongly predicted 10-year disease-free survival in Stage IIB osteogenic sarcoma, with 90% survival for complete versus 54% for little response.
Synapse has enriched 10 related papers. Consider them for comparative context: